{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang M"],"funding":["Fundamental Research Funds for the Central Universities","National Natural Science Foundation of China"],"pagination":["11515-11524"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8447874"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(34)"],"pubmed_abstract":["Stimuli-activatable and subcellular organelle-targeted agents with multimodal therapeutics are urgently desired for highly precise and effective cancer treatment. Herein, a CO/light dual-activatable Ru(ii)-oligo-(thiophene ethynylene) (Ru-OTE) for lysosome-targeted cancer therapy is reported. Ru-OTE is prepared <i>via</i> the coordination-driven self-assembly of a cationic conjugated oligomer (OTE-BN) ligand and a Ru(ii) center. Upon the dual-triggering of internal gaseous signaling molecular CO and external light, Ru-OTE undergoes ligand substitution and releases OTE-BN followed by dramatic fluorescence recovery, which could be used for monitoring drug delivery and imaging guided anticancer treatments. The released OTE-BN selectively accumulates in lysosomes, physically breaking their int"],"journal":["Chemical science"],"pubmed_title":["CO/light dual-activatable Ru(ii)-conjugated oligomer agent for lysosome-targeted multimodal cancer therapeutics."],"pmcid":["PMC8447874"],"funding_grant_id":["GK201901003","21675106","GK202101001","21974084"],"pubmed_authors":["Zhang Z","Wang S","Yang M","Yuan Q","Duan X","Tang Y","Zhao H","Feng Q"],"additional_accession":[]},"is_claimable":false,"name":"CO/light dual-activatable Ru(ii)-conjugated oligomer agent for lysosome-targeted multimodal cancer therapeutics.","description":"Stimuli-activatable and subcellular organelle-targeted agents with multimodal therapeutics are urgently desired for highly precise and effective cancer treatment. Herein, a CO/light dual-activatable Ru(ii)-oligo-(thiophene ethynylene) (Ru-OTE) for lysosome-targeted cancer therapy is reported. Ru-OTE is prepared <i>via</i> the coordination-driven self-assembly of a cationic conjugated oligomer (OTE-BN) ligand and a Ru(ii) center. Upon the dual-triggering of internal gaseous signaling molecular CO and external light, Ru-OTE undergoes ligand substitution and releases OTE-BN followed by dramatic fluorescence recovery, which could be used for monitoring drug delivery and imaging guided anticancer treatments. The released OTE-BN selectively accumulates in lysosomes, physically breaking their int","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-06-01T00:04:29.188Z","creation":"2025-06-01T00:04:29.188Z"},"accession":"S-EPMC8447874","cross_references":{"pubmed":["34667555"],"doi":["10.1039/d1sc01317c"]}}